Details for Patent: 5,716,641
✉ Email this page to a colleague
| Title: | Simethicone containing pharmaceutical compositions |
| Abstract: | A solid oral dosage form for the treatment of gastrointestinal disorders comprising a therapeutically effective amount of a pharmaceutical suitable for the treatment of gastric disorders selected from the group consisting of cimetidine, ranitidine, famotidine, diphenoxylate, loperamide, loperamide-N-oxide, pharmaceutically acceptable salts thereof and combinations thereof; and a therapeutically effective amount of simethicone wherein the pharmaceutical and simethicone are separated by a barrier which is substantially impermeable to simethicone. |
| Inventor(s): | Stevens; Charles A. (Lansdale, PA), Hoy; Michael R. (North Wales, PA), Roche; Edward J. (Paoli, PA) |
| Assignee: | McNeil-PPC, Inc. (Skillman, NJ) |
| Filing Date: | Mar 20, 1996 |
| Application Number: | 08/619,116 |
| Claims: | 1. A method of enhancing the dissolution profile of a pharmaceutical from a solid dosage form comprising the pharmaceutical and simethicone, comprising: providing the pharmaceutical in a first portion of said dosage form, said pharmaceutical is selected from the group consisting of diphenoxylate, loperamide and loperamide-N-oxide, pharmaceutically acceptable salts thereof, and combinations thereof; providing the simethicone in a second portion of said dosage form; and separating said first and second portions with a pharmaceutically acceptable polymeric barrier which is impermeable to simethicone and the pharmaceutical. 2. The method of claim 1 wherein the pharmaceutical is selected from the group consisting of loperamide, loperamide-N-oxide, pharmaceutically acceptable salts thereof and combinations thereof. 3. The method of claim 1 wherein the pharmaceutical comprises loperamide HCl. 4. The method of claim 1 wherein the pharmaceutical comprises diphenoxylate. 5. The method of claim 1 wherein the pharmaceutical comprises loperamide-N-oxide. 6. The method of claim 1 wherein the barrier is a pharmaceutically acceptable film forming polymer. 7. A method of enhancing the dissolution profile of a pharmaceutical from a solid dosage form comprising the pharmaceutical and simethicone, comprising: substantially separating the pharmaceutical from simethicone by providing the pharmaceutical in the form of coated granules, wherein the coating is a nonenteric polymer coating impermeable to the pharmaceutical and simethicone, and the pharmaceutical is selected from the group consisting of diphenoxylate, loperamide and loperamide-N-oxide, pharmaceutically acceptable salts thereof, and combinations thereof; and providing the simethicone in a form free of said nonenteric coating. 8. The method of claim 7 wherein the pharmaceutical is selected from the group consisting of loperamide, loperamide-N-oxide, pharmaceutically acceptable salts thereof and combinations thereof. 9. The method of claim 8 wherein the pharmaceutical comprises loperamide HCl. 10. The method of claim 7 wherein the pharmaceutical comprises diphenoxylate. 11. The method of claim 8 wherein the pharmaceutical comprises loperamide-N-oxide. 12. The method of claim 7 wherein the nonenteric polymeric coating comprises cellulose acetate, methylaminoethyl-methacrylate and neutral methacrylic acid ester and the pharmaceutical comprises loperamide HCl. |
